Chronic musculoskeletal pain among Ebola survivors in Guinea: a cross-sectional study reveals key risk factors and the need for specialized care
- PMID: 40251725
- DOI: 10.1093/rheumatology/keaf212
Chronic musculoskeletal pain among Ebola survivors in Guinea: a cross-sectional study reveals key risk factors and the need for specialized care
Abstract
Objectives: The tremendous size of the 2013-16 West African outbreak of Ebola virus disease (EVD) resulted in a sizeable population of survivors, many reporting short-term sequelae such as arthralgia and myalgia. We aimed to examine the occurrence of chronic musculoskeletal (MS) pain among survivors.
Methods: We performed a cross-sectional study following systematic rheumatological screening of patients included in the PostEboGui cohort (Conakry district). We used regression models to establish the magnitude of EVD as a risk factor for developing chronic MS pain by comparison with a control cohort of seronegative individuals living in the same area and to establish risk factors for developing MS pain among survivors.
Results: The study included 313 patients (55.6% female), with a median age of 28.2 years (interquartile range [IQR] 21-37), and a median time from Ebola Treatment Centre (ETC) discharge to rheumatological visit of 26.2 months (IQR 23-30). Chronic MS pain was reported in 216 (69%) patients. Enthesis and painful peripheral joints were largely involved 196 (91%) with symmetrical distribution. Previous Ebola infection was a major risk factor for chronic MS pain (adjusted odds ratio [aOR], 6.66 [95% CI, 4.52-9.92]). Among survivors, increasing age (OR 1.14, 95% CI 1.08-1.22) and female gender (OR 3.58, 95% CI 1.22-11.80) were both associated with current MS pain, while myalgia experienced during the acute phase of EVD appeared protective (OR 0.14, 95% CI 0.04-0.42).
Conclusion: Our study provides the most accurate long-term description of MS disorders among Ebola survivors. Joint and muscle pain sequelae are frequent and require specialized care.
Keywords: Ebola virus; complications; control group; rheumatic and musculoskeletal disorders; risk factors; sequelae; survivors.
© The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical